410 filings
Page 2 of 21
8-K
p9s572s
27 Dec 23
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
7:48am
424B5
tao7gl
21 Nov 23
Prospectus supplement for primary offering
7:40pm
8-K
w9ndn2
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
utgkyc
7 Nov 23
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial
7:25am
425
2wx25rhz
30 Oct 23
Business combination disclosure
4:42pm
8-K
mu4p0xte6vtydxl
30 Oct 23
Other Events
8:25am
EFFECT
2s6yb9
11 Oct 23
Notice of effectiveness
12:15am
8-K
sgr13p
10 Oct 23
Departure of Directors or Certain Officers
5:12pm
424B3
84f600c sqmoz
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
9divg nj9o9c5
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
CORRESP
ib46muut5a ybz3
6 Oct 23
Correspondence with SEC
12:00am
UPLOAD
8ko14 k2eq
4 Oct 23
Letter from SEC
12:00am
S-4
rvzjz9 ti76w9a7c1
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
DEFA14A
p624373s k6u1p8iz5
31 Aug 23
Additional proxy soliciting materials
5:25pm
8-K
9pt59zstu2x
31 Aug 23
Other Events
5:25pm
425
u5zz8wna6fdymuooo7x
31 Aug 23
Business combination disclosure
8:03am
8-K
hoaog0
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
73cczi45bc
14 Aug 23
Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023
7:48am